List of Femtrace drug patents
Femtrace is owned by Apil.
Femtrace contains Estradiol Acetate.
Femtrace has a total of 1 drug patent out of which 0 drug patents have expired.
Femtrace was authorised for market use on 20 August, 2004.
Femtrace is available in tablet;oral dosage forms.
Femtrace can be used as treatment of moderate to severe vasomotor symptoms associated with menopause.
The generics of Femtrace are possible to be released after 02 October, 2025.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7572779 | APIL | Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
Oct, 2025
(2 years from now) | |
Drugs and Companies using ESTRADIOL ACETATE ingredient
Market Authorisation Date: 20 August, 2004
Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause
Dosage: TABLET;ORAL
FEMTRACE family patents
4
United States
1
Japan
1
Israel
1
New Zealand
1
Australia
1
Norway
1
Mexico
1
Canada
1
China
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic